- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02734199
HER Salt Lake Initiative (HER-SL)
Highly Effective Reversible Contraceptive Initiative-Salt Lake (HER-SL)
Study Overview
Status
Conditions
Detailed Description
The persistently high rate of unintended pregnancy in the US suggests an inadequacy of current prevention models and a need for new approaches to contraceptive acceptability and promotion. Although popularity of Highly Effective Reversible Contraception (HER-C) in the US is steadily increasing, less than 10% of contracepting women use intrauterine devices (IUDs) or subdermal contraceptive implants, which are the most effective methods for avoiding unintended pregnancy.
Poverty is an important predictor of unintended pregnancy where women with incomes below the Federal Poverty Level (FPL) have over a five-fold increased risk of unintended pregnancy relative to women with higher incomes. Because of limited public funds for family planning, low-income women in Salt Lake County have limited access to HER-C, which has high initiation cost but significant cost-saving potential over time. Additionally, contraceptive research has inadequately measured the social impact of HER-C.
The first aim of the HER Salt Lake Initiative is to evaluate the increase in HER-C methods with three strategies: 1) Client centered contraceptive counseling; 2) Removal of financial barriers; and 3) Targeted media campaigns.
The second aim of the HER Salt Lake Initiative is to assess changes in earnings and education among women initiating HER-C compared to other methods of contraception and model the projected lifetime earning potential of women based on their contraceptive method choices.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84102
- Planned Parenthood Association of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Females
- 16-45 years of age
- Seeking contraceptive counseling and services at four participating Planned Parenthood clinics in Salt Lake County
- Desire to prevent pregnancy for at least one year
- Fluent in English or Spanish
- Their current preferred phone number must be functioning at the time of study entry and will be tested prior to enrollment
Exclusion Criteria:
- Currently pregnant and planning to continue the pregnancy, or trying to get pregnant
- Relying on female or male sterilization as contraceptive method
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Enrollment Period 1 Cohort
Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant.
Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
|
|
Enrollment Period 2 Cohort
Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant.
Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
|
|
Enrollment Period 3 Cohort
Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant.
Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Contraceptive method choice and continuation per participant report and medical record documentation
Time Frame: at enrollment through 36 months
|
Assess contraceptive method choice and use in relation to participant demographic and socioeconomic characteristics at enrollment, 12 months, 24 months, and 36 months.
|
at enrollment through 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Federal Poverty Level (FPL) status by participant reported income
Time Frame: at enrollment through 36 months
|
Assess Federal Poverty Level (FPL) at enrollment and 36 months
|
at enrollment through 36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David K Turok, MD, University of Utah, Department of Obstetrics & Gynecology
Publications and helpful links
General Publications
- Gero A, Simmons RG, Sanders JN, Turok DK. Does access to no-cost contraception change method selection among individuals who report difficulty paying for health-related care? BMC Womens Health. 2022 Aug 2;22(1):327. doi: 10.1186/s12905-022-01911-x.
- Higgins JA, Kramer R, Senderowicz L, Everett B, Turok DK, Sanders JN. Sex, poverty, and public health: Connections between sexual wellbeing and economic resources among US reproductive health clients. Perspect Sex Reprod Health. 2022 Mar;54(1):25-28. doi: 10.1363/psrh.12189. Epub 2022 Feb 27.
- Dalessandro C, Kaiser J, Sanders JN. Reproductive autonomy and feelings of control over pregnancy among emerging adult clients in a Utah (USA) contraceptive initiative study. Sex Reprod Healthc. 2022 Mar;31:100688. doi: 10.1016/j.srhc.2021.100688. Epub 2021 Nov 26.
- Kramer RD, Higgins JA, Everett B, Turok DK, Sanders JN. A prospective analysis of the relationship between sexual acceptability and contraceptive satisfaction over time. Am J Obstet Gynecol. 2022 Mar;226(3):396.e1-396.e11. doi: 10.1016/j.ajog.2021.10.008. Epub 2021 Oct 14.
- Myers K, Sanders JN, Dalessandro C, Sexsmith CD, Geist C, Turok DK. The HER Salt Lake media campaign: comparing characteristics and outcomes of clients who make appointments online versus standard scheduling. BMC Womens Health. 2021 Mar 23;21(1):121. doi: 10.1186/s12905-021-01256-x.
- Simmons RG, Sanders JN, Geist C, Gawron L, Myers K, Turok DK. Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants. Am J Obstet Gynecol. 2019 Apr;220(4):376.e1-376.e12. doi: 10.1016/j.ajog.2018.12.022. Epub 2018 Dec 18.
- Higgins JA, Sanders JN, Palta M, Turok DK. Women's Sexual Function, Satisfaction, and Perceptions After Starting Long-Acting Reversible Contraceptives. Obstet Gynecol. 2016 Nov;128(5):1143-1151. doi: 10.1097/AOG.0000000000001655.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 67378
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States